March 17, 2017 10:28 AM EDT
News Briefing

AveX­is shares spike on more pos­i­tive da­ta for SMA gene ther­a­py; Bio­gen stock tanks on fresh skep­ti­cism

Shehla Shakoor

Managing Director

→ AveX­is $AVXS says that 12 of the 12 in­fants suf­fer­ing from spinal mus­cu­lar at­ro­phy (SMA) who were treat­ed with AVXS-101 reached 13.6 months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times